Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
Jonathan And Nancy Fell In Love In Real Life — And So Did Their Stunt Doubles
The Father Who Never Left His Son Behind
This Restaurant's Dog Menu Is Almost As Fancy As The Human Menu
Man’s Best Friend: The Story Behind An Unforgettable Tomb In London
Senior Cat Labeled 'Sad And Scared' Finds Forever Home
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
Two Humpback Whales Fall In Love With A Dog In Incredible Video
Vermont Trooper Jumps Into Frozen Pond To Save Child Trapped Under Ice
Her Reaction To Getting The Baby Cow She’s Always Wanted Has Us All In Tears
Donkey Opens Door, Then Waits Patiently To Be Let In For A Hug
